Render Target: STATIC
Render Timestamp: 2025-03-19T11:11:22.299Z
Commit: 779953b12a5930618aae6aca7c87fb286faeb1d7
XML generation date: 2025-03-07 13:06:39.525
Product last modified at: 2025-01-01T09:06:17.037Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

LRIG1 Antibody #12752

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 142
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    LRIG1 Antibody recognizes endogenous levels of total LRIG1 protein.

    Species Reactivity:

    Human

    The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.

    Species predicted to react based on 100% sequence homology:

    Monkey

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human LRIG1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    Leucine-rich immunoglobulin repeats 1 (LRIG1) is a type I transmembrane protein containing 15 leucine rich repeats and three immunoglobulin domains in the extracellular domain. Researchers characterize LRIG1 as a negative regulator of receptor tyrosine kinase signaling. In studies with ErbB family members and Met kinase, LRIG regulates signaling by increasing ubiquitination and lysosomal degradation of the receptors (1,2). Additional work indicates that LRIG1 plays a role in neurotropic signaling by negatively regulating Ret signaling (3,4). Expression profile studies demonstrate that LRIG1 is a marker in the quiescent population of stem cells in the intestine (5). Interestingly, the genetic ablation of one allele of LRIG1 in mice with an APC+/- background results in development of highly dysplastic adenomas, indicating a role for LRIG1 in tumor suppression (1). Indeed, down-regulation of LRIG1 is tentatively involved in tumor aggressiveness in several tumor types, including glioma (6), head and neck cancer (7), and cervical adenocarcinoma (8).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.